Finanztrends
Deine Einschätzung
Was spricht für und gegen Advanced Proteome Therapeutics in den nächsten Jahren?
Pro
?
M************
?
W******* i* V********
?
U****************
Kontra
?
A****************
?
M****
?
L*********** I********** f** d** n******* J****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Advanced Proteome Therapeutics im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Northwest Biotherapeutics Inc. | 0,00 % | 28,79 % | 6,25 % | -10,53 % | -17,48 % | -62,22 % | -83,50 % |
| Larimar Therapeutics Inc. | -1,71 % | 2,33 % | -5,38 % | 15,79 % | 6,02 % | 3,53 % | -59,07 % |
| Achieve Life Sciences Inc. | 0,89 % | 3,67 % | 10,78 % | 158,58 % | 52,70 % | 17,71 % | -9,60 % |
News
3 Dividend-Paying Industrial Stocks to Buy in August
The summer investing months are typically known for their sleepiness, with action picking up again in the final months to close out the year. But August is also a great time to do some portfolio
ABL Ascend Advanced Therapies ernennt Suman Subramanian zum Chief Business Officer
ROCKVILLE, MD / ACCESS Newswire / 10. August 2026 / ABL Inc. und Ascend Advanced Therapies gaben heute die Ernennung von Suman Subramanian zum Chief Business Officer (CBO) bekannt. Damit
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer
ROCKVILLE, MD /ACCESS Newswire/ August 10, 2026 / ABL Inc and Ascend Advanced Therapiestoday announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further
